News Posts List
Small Study Shows 90% Benefit Rate in Papillary Kidney Cancer
12/01/2009
CHICAGO -- Almost all patients with papillary renal carcinoma had stable disease or better response to treatment with a drug that targets multiple growth factors, preliminary data from an ongoing trial showed. Daily and intermittent dosing with foretinib resulted in a total clinical benefit greater than 90%, according to researchers here at the International Kidney Cancer Symposium.
Notes from the 8th International Symposium
11/18/2009
Lance Armstrong's LIVESTRONG Army now in AK
11/14/2009
Kidney cancer took Alger's cousin Sheri Stears. Melanoma skin cancer killed her best friend Carrie Forrest.
Curbing Obesity: This Could Take Awhile
11/04/2009
Elementary-age girls who spend at least 70 minutes per week in phys ed consistently do better on standardized reading and math tests than girls who spend less than 35 minutes.
NCCN Guidelines for Kidney Cancer Updated
11/03/2009
Report from iSBTc Annual Meeting
10/31/2009
Kidney Cancer Highlights
10/30/2009
The surgical and medical treatment of renal cell carcinoma (RCC) has changed dramatically in the last several years and continues to constantly evolve.
How may we help you?
10/26/2009
There is information and assistance for patients, survivors, and caregivers on this website. Your participate is welcome. There is no charge for membership.
Votrient Approved for Advanced Kidney Cancer
10/23/2009
Designed to thwart blood vessel growth in tumors
News Feed